Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1345706 | 1.00 | GPR139 (0.43) | GPR139AAK1TRPA1CTSSCTSK | |
| SCHEMBL17041588 | 0.86 | TRPA1 (0.44) | GPR139AAK1TRPA1CTSSCTSK | |
| SCHEMBL31706042 | 0.84 | PPARG (0.41) | AAK1PPARG | |
| SCHEMBL27796927 | 0.84 | GABRB1 (0.41) | AAK1TRPA1CTSSCTSKTSHR | |
| SCHEMBL31705557 | 0.84 | PPARG (0.41) | AAK1PPARG | |
| SCHEMBL30493109 | 0.84 | TRPA1 (0.42) | AAK1TRPA1CTSSCTSKTSHR | |
| SCHEMBL31733775 | 0.84 | CYP1A2 (0.50) | AAK1PPARG | |
| SCHEMBL2441134 | 0.83 | MAPT (0.41) | AAK1TRPA1CTSSCTSKTSHR | |
| SCHEMBL29945748 | 0.83 | TRPA1 (0.41) | AAK1TRPA1CTSSCTSKTSHR | |
| SCHEMBL31733813 | 0.83 | MAPT (0.41) | AAK1TRPA1CTSSCTSKTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063035-B2 | Triazolyl aminopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | GPR139 4010/4885AAK1 1933/4885TRPA1 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.